Treatment of dyslipidemia and coronary atherosclerosis
Conditions
Interventions
Study Groups:NA
Sponsors
Zhejiang Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients with confirmed atherosclerotic cardiovascular disease (ASCVD) or hypercholesterolemia who have used PCSK-9 inhibitors. Patients are >= 18 years old, voluntarily participate in the study, and sign the informed consent form; 2.Be able to articulate your feelings and opinions.
Exclusion criteria
Exclusion criteria: 1. Presence of severe liver and kidney dysfunction, neurological disease, or other diseases that may affect the drug experience; 2. Cognitive dysfunction and inability to accurately express one's feelings; 3. Patients who are unwilling or unable to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main factors that lead to the discontinuation of PCSK-9 drugs; | — |
Countries
China
Contacts
Public ContactHu Ying
Zhejiang Provincial People's Hospital
Outcome results
None listed